Clinical Trials Logo

Nicotine clinical trials

View clinical trials related to Nicotine.

Filter by:

NCT ID: NCT03102931 Completed - Oxidative Stress Clinical Trials

Switching to Low Oxidant Content Cigarettes in Adult Smokers

Start date: July 11, 2017
Phase: N/A
Study type: Interventional

The overall objective of this clinical study is to determine if smokers who switch from their usual high reactive oxygen and nitrous oxide species (ROS/NOS) products to a low ROS/NOS product exhibit increased or decreased levels of oxidative stress/damage, respectively.

NCT ID: NCT03010995 Withdrawn - Nicotine Clinical Trials

The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study

ACE
Start date: March 13, 2018
Phase: Phase 1
Study type: Interventional

The goal of this project is to evaluate the nicotine induced acute cardiovascular changes in E-Cigarette users and also study the mechanism involved particularly with vascular impairment.

NCT ID: NCT01227343 Completed - Nicotine Clinical Trials

Nicotine and Brain Imaging Research Study

Start date: March 2010
Phase:
Study type: Observational

The aim of this study is to assess the impact of smoking on cortical GABA levels in males and females. Using magnetic resonance spectroscopy (MRS), we will examine the impact of sex and menstrual cycle phase on brain neurochemistry in healthy smokers and non-smokers. We hypothesize that female, but not male, smokers will have reduced cortical GABA levels compared to their non-smoking, sex-matched counterparts.

NCT ID: NCT01223404 Completed - Clinical trials for Magnetic Resonance Imaging

Nicotinic Modulation of the Default Network

Start date: October 2010
Phase: N/A
Study type: Interventional

Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed thought when the mind is free to wander. There is indication that nicotine may improve attention by aiding the deactivation of the default network, and this mechanism may be of therapeutic benefit for the above disease states. The current project aims at providing a proof of concept by demonstrating that nicotinic drugs modulate default network function. The nicotinic agonist nicotine is hypothesized to improve attention by facilitating the down-regulation of default network activity, and the nicotinic antagonist mecamylamine is hypothesized to impair attention by impeding the down-regulation of default network activity during attentional task performance.